2022 Impact Factor
2.3

EDITORS IN CHIEF
M. B. Bilò (Italy)
P. Carreiro-Martins (Portugal)

DEPUTY EDITORS

R. Rodrigues Alves (Portugal)
D. Villalta (Italy)

ASSOCIATE EDITORS

R. Asero (Italy)
M. Branco Ferreira (Portugal)

L. Cecchi (Italy)
E. Scala (Italy)
D. Solé (Brasil)
G. Sturm (Austria)

EDITORIAL BOARD
I. Agache (Romania)
I. Annesi Maesano (France)
L. Antonicelli (Italy)
G. Azizi (Iran)
L.M. Borrego (Portugal)
K. Brockow (Germany)
S. Bavbek (Turkey)
E. Cichocka-Jarosz (Poland)
M. Cugno (Italy)
L. Delgado (Portugal)
P. Demoly (France)
G. D'Amato (Italy)
S. Durham (UK)
M. Faber (Belgium)
M. Fernandez-Rivas (Spain)
J. Fonseca (Portugal)
ZS. Gao (China)
G.P. Girolomoni (Italy)
E. Goudouris (Brasil)
A. Grumach (Brasil)
G. Kostantinou (Greece)
F. Levi-Shaffer (Israel)
M. Maurer (Germany)
L. Mayorga (Spain)
C. Micheletto (Italy)
M. Morais de Almeida (Portugal)
G. Moscato (Italy)
A. Musarra (Italy)
C. Nunes (Portugal)
M. Ollert (Lussemburgo)
P. Parronchi (Italy)
G. Passalacqua (Italy)
E. Pedro (Portugal)
A. Perino (Italy)
O. Quercia (Italy)
A. Romano (Italy)
G. Scadding (UK)
A. Todo Bom (Portugal)
A. Tedeschi (Italy)
R. van Ree (Netherland)
S. Voltolini (Italy)

FOUNDERS

F. Bonifazi (Italy)
A. Sabbah (France)

*************************

Chief Executive Officer
Ludovico Baldessin

Editorial Coordinator
Barbara Moret

Publishing Editor
Jessica Guenzi
j.guenzi@lswr.it

Sales

dircom@lswr.it

EDRA SpA
Via G. Spadolini, 7

20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301
www.edraspa.it

Follow us on LinkedIn

Table of Contents »

Healthcare costs associated with allergic rhinitis, asthma and allergy immunotherapy

F. Tesch denise.kuester@uniklinikum-dresden.de¹, A. Domdey², T. S. Grand², E. Wuestenberg², L. Elliott², J. Schmitt¹, D. Küster¹

Show more: Authors information and Publication History

Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.126

Summary
Allergic rhinitis (AR) and asthma are chronic diseases in which the airways become inflamed in response to allergens. Allergy immunotherapy (AIT) is recommended for those unable to manage symptoms using pharmacotherapy. This study estimated healthcare costs and utilisation for patients with AR and asthma. Mean annual outpatient visits, pharmaceutical costs and inpatient hospitalisations were calculated for 2010 and 2014, with pharmaceutical and inpatient costs stratified by AIT use. AR and asthma patients had a 35% higher mean number of physician visits and up to 90% higher mean pharmaceutical costs compared to controls. The cost of pharmaceuticals and inpatient hospitalisations were 54% lower in those prescribed AIT. Further research is recommended to understand the reasons for these cost differences.

Key words
Allergic rhinitis; allergy treatment; asthma treatment; cost analysis; immunotherapy.

Cite this article as:
Tesch F, Domdey A, Grand TS, Wuestenberg E, Elliott L, Schmitt J, Küster D, Healthcare costs associated with allergic rhinitis, asthma and allergy immunotherapy, Eur Ann Allergy Clin Immunol., 2020;52(4): 165-174. doi:10.23822/EurAnnACI.1764-1489.126.

FULL TEXT